Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2022 / Aug / A Cornea Copia… and Other News
Anterior Segment Cornea Research & Innovations

A Cornea Copia… and Other News

We share some of the most interesting recent cornea and ocular surface research

By Geoffrey Potjewyd 8/30/2022 2 min read

Share

Credit: Image sourced from Shutterstock.com

Monkey see? Researchers have developed a non-human primate model of desiccating stress-induced dry eye disease using Rhesus macaque monkeys. The monkeys demonstrated similar clinical symptoms to those shown by humans. Additionally, they showed increased corneal fluorescein staining and decreased tear-film break up time after corticosteroid treatment (1).

Never forget. Tissue-resident memory T cells have been imaged patrolling the surface of healthy human corneas for the first time, indicating that they form in response to ocular infection and remain once the infection has been fought to provide local protective immunity and prevent secondary attacks by the same antigen (2).

Pain management. Severe neuropathic dry eye-like pain reversed in three patients by treating occult surface disease. Patients either responded after 48 hours of significantly relieving the symptoms, or one week after treating superior conjunctivochalasis. Rigorous testing of surface disease may avoid systemic treatments that could cause serious side-effects (3).

Tear jerker. Researchers develop a method to identify biomarkers of health and disease from the proteome of tear fluid. The non-invasive technique uses mass spec to analyze the tear film of the eye, which may one day be used for diagnosing ocular diseases, or even neurodegenerative diseases such as Alzheimer’s disease (4).

Diagnosing discomfort. Contact lens-induced discomfort is often a cause for people to stop using their lenses. There is an increase in ocular surface immune cells following this discomfort, which exemplifies the importance of immune system awareness during lens development and when treating ocular surface pain (5).

Pollution problems. Air pollution causes ocular discomfort and damage, as well as tear film instability. Particulate matter and other air-based pollutants influenced dry eye disease through separate mechanisms and at differing rates (6).

The thick of it. Corneal parameters heritable in families with keratoconus – genes associated with corneal thickness – warrant further investigation. Pachymetry indices could potentially be used as predictors of keratoconus occurrence (7).

Dry eye relief. A mucomimetic and antioxidant-based eye drop is effective at treating diabetic dry eye, and implies a usefulness for treating ocular surface defects with antioxidants (8).

Stopping scarring. The combination of losartan and prednisolone acetate reduces corneal scarring following alkali burns in rabbits. Further study is needed to determine effectiveness as a clinical therapy in humans (9).

References

  1. L Gong et al., Sci Rep, 12, 7957 (2022). PMID: 35562371.
  2. JK Loi et al., Cell Rep, 39, 110852 (2022). PMID: 35613584.
  3. SL Maskin, Am J Ophthalmol Case Rep, 27, 101662 (2022). PMID: 35873369.
  4. G Jones et al., Int J Mol Sci, 23, 2307 (2022). PMID: 35216421.
  5. AP Nair et al., Transl Vis Sci Technol, 11, 16 (2022). PMID: 35857328.
  6. R Hao et al., Front Med, 9, 909330 (2022). PMID: 35872759.
  7. Y Wang et al., Transl Vis Sci Technol, 11, 13 (2022). PMID: 35838491.
  8. AM Roszkowska et al., Front Biosci, 27, 202 (2022). PMID: 35866400.
  9. LP Sampaio et al., Transl Vis Sci Technol, 11, 9 (2022). PMID: 35819289.

About the Author(s)

Geoffrey Potjewyd

The lion’s share of my PhD was spent in the lab, and though I mostly enjoyed it (mostly), what I particularly liked was the opportunity to learn about the latest breakthroughs in research. Communicating science to a wider audience allows me to scratch that itch without working all week only to find my stem cell culture has given up the ghost on the Friday (I’m not bitter). Fortunately for me, it turns out writing is actually fun – so by working for Texere I get to do it every day, whilst still being an active member of the clinical and research community.

More Articles by Geoffrey Potjewyd

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: